---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056413"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:03:50.204742+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant

## Summary
- Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.
- Cash of $94.0M as of Sept 30, 2021; company funded into 2023.
- Phase 2 ALS study nearing full enrollment; topline data expected 1H 2022.
- IND clearance for AT-1501 in islet cell transplantation; kidney and IgAN trials expected Q4 2021 start.
- Research collaboration with CareDx for renal transplant biomarkers and predictive algorithms.

## SEC filing metadata
- accession: 0001564590-21-056413
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/0001564590-21-056413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/eldn-8k_20211111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056413
- JSON: https://secwatch.observer/filing/0001564590-21-056413.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.